Experience with moricizine HCl in children with supraventricular tachycardia

International Journal of Cardiology
A V MehtaR J Kanter

Abstract

Eight children, age between 4.5 and 19 years were treated with moricizine for supraventricular tachycardia during the last 3 years. The tachycardia was documented by surface electrocardiogram (ECG), and/or by ambulatory ECG in all the children and the mechanism of tachycardia was determined by previously published surface ECG and electrophysiologic criteria in all but one child. Of the eight children, three had atrial ectopic tachycardia, three had automatic junctional ectopic tachycardia, one had atrioventricular (AV) nodal reentry tachycardia and one had atrial reentry. All the children except one had failed trial of two or more antiarrhythmic drugs prior to moricizine therapy. The duration of moricizine therapy ranged from 4 days to 25 months. In three of the eight children (patients 3, 5 and 7), who presented with AV nodal reentrant tachycardia, automatic junctional ectopic tachycardia and atrial ectopic tachycardia, respectively, moricizine therapy was effective in restoring sinus rhythm and controlling the clinical tachycardia. Only one child (patient 1) developed proarrhythmia, an episode of fast, narrow-QRS supraventricular tachycardia lasting for 30 s, on the third day of therapy. This was subsequently confirmed by ele...Continue Reading

References

Oct 1, 1992·Journal of the American College of Cardiology·T PaulH C Kallfelz
Jul 1, 1991·DICP : the Annals of Pharmacotherapy·B J McGrath, S Stoukides
Jan 1, 1990·Cardiology·L S Dreifus, S E Hessen
Feb 20, 1990·The American Journal of Cardiology·S A Mahler, R M Borland
Feb 20, 1990·The American Journal of Cardiology·J T Bigger
Oct 16, 1987·The American Journal of Cardiology·V L EvansD G McNamara
Feb 1, 1988·Journal of the American College of Cardiology·A V MehtaR M Donner

❮ Previous
Next ❯

Citations

Oct 1, 1995·Journal of Clinical Pharmacology·P J RiceA V Mehta
Dec 21, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joshua S RodeferJørn Arnt
Apr 5, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Corina O BondiDavid A Morilak
Feb 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alvin V TerrySahebarao P Mahadik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.